Balyasny Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.9M Buy
296,900
+239,900
+421% +$11.4M 0.01% 997
2025
Q4
$2.9M Sell
57,000
-299,600
-84% -$15.3M ﹤0.01% 1686
2025
Q3
$19.8M Buy
356,600
+352,400
+8,390% +$20.6M 0.03% 723
2025
Q2
$290K Sell
4,200
-113,600
-96% -$7.73M ﹤0.01% 2483
2025
Q1
$8.18M Sell
117,800
-382,300
-76% -$31.6M 0.01% 1030
2024
Q4
$43M Buy
+500,100
New +$54.1M 0.06% 369
2024
Q1
Sell
-300,000
Closed -$31M 2958
2023
Q4
$31M Buy
+300,000
New +$29.7M 0.06% 437
2023
Q3
Sell
-182,000
Closed -$14.7M 2577
2023
Q2
$14.7M Buy
+182,000
New +$14.9M 0.03% 634
2021
Q3
Sell
-260,000
Closed -$10.9M 2280
2021
Q2
$10.9M Buy
+260,000
New +$10.1M 0.05% 489
2020
Q1
Sell
-1,100,000
Closed -$31.8M 1415
2019
Q4
$31.8M Buy
1,100,000
+700,000
+175% +$19.4M 0.19% 159
2019
Q3
$10.3M Buy
+400,000
New +$10.1M 0.07% 384
2019
Q1
Sell
-360,000
Closed -$8.29M 1567
2018
Q4
$8.29M Sell
360,000
-60,000
-14% -$1.33M 0.06% 392
2018
Q3
$9.9M Sell
420,000
-370,000
-47% -$9.03M 0.04% 493
2018
Q2
$18.2M Buy
+790,000
New +$18.8M 0.08% 335

Other funds holding NVO

Balyasny Asset Management's NVO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Novo Nordisk (NVO) stake by 25% in Q1 2026, selling an estimated $5.92M and leaving 383,146 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #855.

Balyasny Asset Management first reported a position in NVO in Q1 2018 and has held it in 21 quarters since. The position peaked at $106M in Q2 2025. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Balyasny Asset Management held 383,146 shares of Novo Nordisk worth $14.1M as of Q1 2026.
  • Balyasny Asset Management sold 124,963 Novo Nordisk shares in Q1 2026, an estimated $5.92M.
  • Novo Nordisk made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #855 holding.
  • Balyasny Asset Management first reported a position in Novo Nordisk in Q1 2018 and has held it in 21 quarters since.
  • Balyasny Asset Management's Novo Nordisk position peaked at $106M in Q2 2025.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.